• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺特异性膜抗原在LNCaP前列腺癌细胞系中的定位

Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line.

作者信息

Troyer J K, Beckett M L, Wright G L

机构信息

Department of Microbiology and Immunology, Virginia Prostate Center, Eastern Virginia Medical School, Norfolk 23501, USA.

出版信息

Prostate. 1997 Mar 1;30(4):232-42. doi: 10.1002/(sici)1097-0045(19970301)30:4<232::aid-pros2>3.0.co;2-n.

DOI:10.1002/(sici)1097-0045(19970301)30:4<232::aid-pros2>3.0.co;2-n
PMID:9111600
Abstract

BACKGROUND

Prostate-specific membrane antigen (PSMA) is a novel prostate biomarker overexpressed in poorly differentiated and metastatic prostate carcinomas and apparently upregulated following hormone-ablation therapy. PSMA appears to be a satisfactory target for antibody-directed imaging of prostate carcinomas despite the recent finding that the antigenic epitope recognized by monoclonal antibody (MAb) 7E11-C5 is found in the cytoplasmic domain of this transmembrane glycoprotein [Troyer et al.: Urol Oncol 1:29-37, 1995]. This finding prompted the present investigation to precisely define the cellular location of PSMA in the LNCaP prostate carcinoma cell line, the line used to generate MAb 7E11-C5.

METHODS

Subcellular fractionation, immunofluorescence and immunoperoxidase staining of live and fixed cells, and immunoelectron microscopy were used to determine the localization of PSMA in LNCaP cells.

RESULTS

PSMA was found to be localized at the inner face of the plasma membrane as well as being associated with mitochondria. Staining of LNCaP cells, treated by serum starvation followed by serum stimulation, showed no changes in the typical cytoplasmic staining pattern.

CONCLUSIONS

The data suggest that the PSMA target epitope for antibody-directed imaging with MAb 7E11-C5 only becomes accessible upon apoptosis or necrosis. This further suggests that antibodies directed at the extracellular domain may enhance the sensitivity of antibody-directed imaging and therapy of prostate carcinomas by recognizing surface epitopes of PSMA on living cancer cells.

摘要

背景

前列腺特异性膜抗原(PSMA)是一种新型的前列腺生物标志物,在低分化和转移性前列腺癌中过表达,并且在激素消融治疗后明显上调。尽管最近发现单克隆抗体(MAb)7E11-C5识别的抗原表位存在于这种跨膜糖蛋白的胞质结构域中,但PSMA似乎是前列腺癌抗体导向成像的一个令人满意的靶点[特罗耶等人:《泌尿肿瘤学》1:29 - 37,1995年]。这一发现促使本研究精确确定PSMA在LNCaP前列腺癌细胞系中的细胞定位,该细胞系用于产生MAb 7E11-C5。

方法

采用亚细胞分级分离、活细胞和固定细胞的免疫荧光及免疫过氧化物酶染色以及免疫电子显微镜技术来确定PSMA在LNCaP细胞中的定位。

结果

发现PSMA定位于质膜内表面以及与线粒体相关。对LNCaP细胞进行血清饥饿后再血清刺激处理,染色显示典型的胞质染色模式没有变化。

结论

数据表明,用MAb 7E11-C5进行抗体导向成像的PSMA靶表位仅在细胞凋亡或坏死时才会暴露。这进一步表明,针对细胞外结构域的抗体可能通过识别活癌细胞上PSMA的表面表位来提高前列腺癌抗体导向成像和治疗的敏感性。

相似文献

1
Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line.前列腺特异性膜抗原在LNCaP前列腺癌细胞系中的定位
Prostate. 1997 Mar 1;30(4):232-42. doi: 10.1002/(sici)1097-0045(19970301)30:4<232::aid-pros2>3.0.co;2-n.
2
Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients.对源自LNCaP细胞、前列腺癌肿瘤及前列腺癌患者血清的前列腺特异性膜抗原的糖基化分析。
Prostate Suppl. 1996;7:25-9.
3
Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector.通过用前列腺特异性膜抗原(PSMA)DNA载体进行疫苗接种诱导抗前列腺特异性膜抗原(PSMA)的抗体。
Eur Urol. 2002 Jul;42(1):67-73. doi: 10.1016/s0302-2838(02)00211-7.
4
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.针对前列腺特异性膜抗原细胞外结构域的放射性标记单克隆抗体:在携带LNCaP人前列腺肿瘤的裸鼠中的临床前研究
J Nucl Med. 2003 Apr;44(4):610-7.
5
Monoclonal antibody 7E11.C5 staining of viable LNCaP cells.活LNCaP细胞的单克隆抗体7E11.C5染色
Prostate. 1997 Jan 1;30(1):65-8. doi: 10.1002/(sici)1097-0045(19970101)30:1<65::aid-pros10>3.0.co;2-n.
6
In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.前列腺特异性膜抗原细胞外结构域特异性放射性标记单克隆抗体的体外特性研究
Cancer Res. 2000 Sep 15;60(18):5237-43.
7
Constitutive and antibody-induced internalization of prostate-specific membrane antigen.前列腺特异性膜抗原的组成型及抗体诱导的内化作用
Cancer Res. 1998 Sep 15;58(18):4055-60.
8
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.五种不同的抗前列腺特异性膜抗原(PSMA)抗体证实了PSMA在肿瘤相关新生血管中的表达。
Cancer Res. 1999 Jul 1;59(13):3192-8.
9
Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.血清前列腺特异性膜抗原的检测,一种前列腺癌新的预后标志物。
Urology. 1998 May;51(5A Suppl):89-97. doi: 10.1016/s0090-4295(98)00082-x.
10
Measurement of prostate-specific membrane antigen in the serum with a new antibody.使用一种新型抗体检测血清中的前列腺特异性膜抗原。
Prostate. 1996 Apr;28(4):266-71. doi: 10.1002/(SICI)1097-0045(199604)28:4<266::AID-PROS7>3.0.CO;2-B.

引用本文的文献

1
Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?人类ABC和SLC转运蛋白:导致PSMA - 617非特异性摄取的罪魁祸首?
Pharmaceuticals (Basel). 2024 Apr 16;17(4):513. doi: 10.3390/ph17040513.
2
Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.前列腺特异性膜抗原(PSMA)治疗寡转移前列腺癌的治疗学。
Int J Mol Sci. 2021 Nov 9;22(22):12095. doi: 10.3390/ijms222212095.
3
PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties.
PSMA-D4 放射性配体靶向治疗前列腺癌:合成、特性和生物学特性初步评估。
Int J Mol Sci. 2021 Mar 8;22(5):2731. doi: 10.3390/ijms22052731.
4
Design and Evaluation of Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy-Part I.用于前列腺癌治疗的镭标记及抗前列腺特异性膜抗原靶向钠A型纳米沸石的设计与评估——第一部分。
Materials (Basel). 2020 Sep 2;13(17):3875. doi: 10.3390/ma13173875.
5
Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.5D3-DM1 的研发:一种用于 PSMA 阳性前列腺癌治疗的新型抗前列腺特异性膜抗原抗体药物偶联物。
Mol Pharm. 2020 Sep 8;17(9):3392-3402. doi: 10.1021/acs.molpharmaceut.0c00457. Epub 2020 Aug 17.
6
Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives.前列腺癌的靶向放射性核素治疗——从基础研究到临床视角。
Molecules. 2020 Apr 10;25(7):1743. doi: 10.3390/molecules25071743.
7
Imaging as a Personalized Biomarker for Prostate Cancer Risk Stratification.成像作为前列腺癌风险分层的个性化生物标志物
Diagnostics (Basel). 2018 Nov 30;8(4):80. doi: 10.3390/diagnostics8040080.
8
Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer.正电子发射断层显像(PET)成像在前列腺癌初始治疗后生化复发中的作用
Transl Androl Urol. 2018 Sep;7(Suppl 4):S462-S476. doi: 10.21037/tau.2018.06.09.
9
Evaluation of In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen.评价 In-DOTA-5D3,一种用于前列腺特异性膜抗原放射性免疫治疗的替代 SPECT 成像剂。
J Nucl Med. 2019 Mar;60(3):400-406. doi: 10.2967/jnumed.118.214403. Epub 2018 Sep 20.
10
A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies.PSMA 生物学、PSMA 成像和内放射治疗策略不断演变的故事述评。
J Nucl Med. 2018 Jul;59(7):1007-1013. doi: 10.2967/jnumed.117.203877. Epub 2018 Apr 19.